Cargando…

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2022
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793941/ https://www.ncbi.nlm.nih.gov/pubmed/35086825 http://dx.doi.org/10.1136/bmj.o239

Ejemplares similares

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
por: Valgimigli, Marco, et al.
Publicado: (2021)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Publicado: (2016)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis
Publicado: (2014)

Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials
por: Maharaj, Ritesh, et al.
Publicado: (2011)

Safety Comparison of Monotherapy Aspirin to Dual Antiplatelet Therapy Following Coronary Artery Bypass Surgery
por: Nei, Scott D., et al.
Publicado: (2022)

P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Yu, Yanqiao, et al.
Publicado: (2023)

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022)

Aspirin Monotherapy beyond 12 Months of Dual Antiplatelet Therapy in Patients with Acute Myocardial Infarction: Oldies But Goodies?
por: Suh, Jung-Won
Publicado: (2019)

Psychometric validation of the Coronary Revascularisation Outcome Questionnaire (CROQv2) in the context of the NHS Coronary Revascularisation PROMs Pilot
por: Schroter, Sara, et al.
Publicado: (2017)

Dual Antiplatelet Therapy with Parenteral P2Y(12) Inhibitors: Rationale, Evidence, and Future Directions
por: Alagna, Giulia, et al.
Publicado: (2023)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Systematic review and meta-analysis of optimal P2Y(12) blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome
por: Rossington, Jennifer A, et al.
Publicado: (2016)

Correction: Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis — coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial
Publicado: (2018)

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease
por: Krackhardt, Florian, et al.
Publicado: (2022)

Timing and completeness of revascularisation in acute coronary syndromes
por: Sanz-Sánchez, Jorge, et al.
Publicado: (2022)

Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor
por: ten Haaf, Monique E., et al.
Publicado: (2023)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review
por: Sherwood, Matthew W., et al.
Publicado: (2015)

Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265]
por: Taggart, David P, et al.
Publicado: (2006)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy
por: Polo Friz, Hernan, et al.
Publicado: (2015)

Coronary revascularisation in a patient with dextrocardia with situs inversus
por: Siddiqi, MS
Publicado: (2013)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

How to select patients requiring coronary revascularisation using coronary physiology
por: Modi, Bhavik, et al.
Publicado: (2021)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

To Revascularise or Not To Revascularise, That Is the Question: the Diagnostic and Management Conundrum of Ischaemic Cardiomyopathy
por: Briceno, Natalia, et al.
Publicado: (2016)

P2Y12 Inhibitors Exacerbate Low-dose Aspirin-induced Small Bowel Injury in Dual Antiplatelet Therapy
por: Handa, Yukiko, et al.
Publicado: (2021)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials
por: Bularga, Anda, et al.
Publicado: (2021)

Abatement of potent P2Y12 antagonist-based dual antiplatelet therapy after coronary intervention: A network meta-analysis of randomized controlled trials
por: El Alaoui El Abdallaoui, Oumaima, et al.
Publicado: (2023)

Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation
por: Piek, Jan J, et al.
Publicado: (2015)

The stent in the high-bleeding risk patient: antiplatelet monotherapy?
por: Capranzano, Piera
Publicado: (2022)

Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors
por: Byun, Sungwook, et al.
Publicado: (2022)

P2Y12 blocker monotherapy after percutaneous coronary intervention
por: Verheugt, F. W. A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sc6jtveua3sf6fjp1spd9cr5i0